Company intelligence / Profile preview

Suzhou Intragrand Pharma

Ownership: Private
Development stage: Preclinical

Overview

Suzhou Intragrand Pharma is a start-up biotech company focused on novel drug discovery and development for inflammation, fibrosis, and other unmet clinical needs. Its lead program is ITG-1052 (lenamilast), an investigational inhaled PDE4 inhibitor targeting idiopathic pulmonary fibrosis and other respiratory indications. The company recently licensed this asset to Transpire Bio for all territories except China.

Therapeutic areas: PulmonologyImmunologyOther
Modalities: Small moleculeInhaled drug delivery therapy
Industry: Biotech

Drug pipeline

1 asset

lenamilast

Pre-clinical

Indications: Idiopathic pulmonary fibrosis, Respiratory diseases

Partnerships

Transpire Bio Inc. – exclusive license agreement for ITG‑1052 outside China

Beyond the preview

Go deeper on Suzhou Intragrand Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Intragrand Pharma.

Explore the full profile